Large-cell lung carcinoma with rhabdoid phenotype
|Large Cell Lung Carcinoma with Rhabdoid Phenotype|
|Classification and external resources|
Large cell lung carcinoma with rhabdoid phenotype (LCLC-RP) is a rare histological form of lung cancer, currently classified as a variant of large cell lung carcinoma (LCLC). In order for a LCLC to be subclassified as the rhabdoid phenotype variant, at least 10% of the malignant tumor cells must contain distinctive structures composed of tangled intermediate filaments that displace the cell nucleus outward toward the cell membrane. The whorled eosinophilic inclusions in LCLC-RP cells give it a microscopic resemblance to malignant cells found in rhabdomyosarcoma (RMS), a rare neoplasm arising from transformed skeletal muscle. Despite their microscopic similarities, LCLC-RP is not associated with rhabdomyosarcoma.
Although rhabdoid variants of LCLC are sometimes referred to as "rhabdoid carcinomas", this particular term should be reserved for examples of "pure" rhabdoid neoplasms (i.e. those that do not contain cells containing other histological variants)
Although Colby and colleagues were the first to report a primary lung cancer with a rhabdoid phenotype in a paper published in 1995, cells with these characteristic features had been previously noted in 1978, when they were noted to occur in a rare and extremely aggressive form of kidney cancer that appears almost exclusively in young children called "Wilms tumor".
LCLC-RP were first recognized as a distinct entity under the 3rd (published in 1999) revision of the World Health Organization (WHO) lung tumor histological typing scheme. Its placement in the classification schema went unchanged during the 2004 revision.
Lung cancers are now considered a large and extremely heterogeneous family of neoplasms that feature widely varying genetic, biological, and clinical characteristics. About 50 different lung cancer variants are recognized under the 2004 revision of the World Health Organization ("WHO-2004") histological typing system, the most widely recognized and used lung cancer classification scheme. Recent studies have shown beyond doubt that the old classification paradigm of "small cell carcinoma vs. non-small cell carcinoma" is now obsolete, and that the correct "subclassification" of lung cancer cases is necessary to assure that patients receive optimum management.
More than 99% of primary lung cancers are carcinoma, which are tumors composed of cells that originate from embryonic ectoderm or endoderm, or that feature epithelial characteristics or differentiation. Eight major groups of lung carcinomas are recognized in WHO-2004:
LCLC-RP are considered variants of large cell carcinoma.
While occasional scattered rhabdoid cell formation occurs with considerable frequency in lung carcinomas, this is not considered to be of clinical significance. According to current classification criteria, a tumor can only be diagnosed as LCLC-RP when an undifferentiated large-cell lung carcinoma contains a rhabdoid cell component that makes up at least 10% of the tumor mass.
- Oval to polygonal cell shape
- Eosinophilic, hyaline-like perinuclear agglomerations of intermediate filaments
- Compressed, eccentric nuclei
- Prominent central macronucleoli (one or two)
- Abundant eosinophilic cytoplasm
- Reticular chromatin pattern
The differential diagnosis of LCLC-RP includes secondary metastatic lesions, melignant melanoma of the lung with rhabdoid phenotype, mucinous adenocarcinomas (particularly those featuring signet-ring cells), rhabdomyosarcoma, epitheloid angiosarcoma, pleural mesothelioma, and plasmacytoma.
On radiological imaging, most cases of LCLC-RP are single "coin lesions" or discrete masses, but cases presenting as multiple nodules throughout the lung have also been noted. Cases with inhomogeneous-appearing consolidation on CT have been reported, as well as aerogenous, lepidic-type spread. Some large, centrally located LCLC-RP have been noted to show signs of gross necrosis and cavitation on imaging studies, as well as being associated with the presence of large bullae.
Results of immunohistochemistry (IHC) staining in rhabdoid lung cancers tends to reflect the multiphasic nature of these tumors. Typically, markers expressed in LCLC-RP include those seen in "generic" NSCLC's, such as epithelial membrane antigen (EMA, 61%), various cytokeratins (CK's, 80%), and markers associated with the underlying "parent" pulmonary carcinoma. Expression of immunomarkers in the rhabdoid cells, however, have often been noted to be weaker and more diffuse than those in the more differentiated tumor cells. They also more frequently express "non-carcinomatous" markers typically associated with "dedifferentiated" neoplasms. Interestingly, expression of thyroid transcription factor-1 (TTF-1), a commonly used marker for primary lung cancers, appears to be less frequent in rhabdoid carcinomas than in most other histotypes of pulmonary cancers.
Vimentin, an intermediate filament protein usually found in sarcoma, is ubiquitously (nearly 100%) expressed diffusely throughout the cytoplasm of the rhabdoid cells, and is often intermingled with CK's in their whorled inclusions. Some studied have reported that neuroendocrine-related markers (i.e. neuron-specific enolase (NSE), neural cell adhesion molecule (NCAM), chromogranin A (CgA), synaptophysin), are also quite frequently expressed in a significant proportion of rhabdoid cells.
Histogenesis and genetics
The histogenesis of most lung cancers is not well understood. Carcinomas of the lung are thought to arise from the uncontrolled growth of mutated, transformed, multipotent "cancer stem cells" with epithelial characteristics or lineage. When viewed under a light microscope, the transformed cancer cells in LCLC are undifferentiated, lacking specific cytological and tissue architectural characteristics of other types, subtypes, and variants of lung cancer. Election microscopic studies, however, have shown that many LCLC do have ultrastructural characteristics of other tumor types (i.e. adenocarcinoma, squamous cell carcinoma)., and that rhabdoid carcinomas often show similar features.
Some evidence suggests that cells with the rhabdoid phenotype result from mutations occurring in some of the cells descending from the "parent" tumor, leading to the "emergence" of distinct populations of characteristic cells with the rhabdoid phenotype within the parent neoplasm, often in the peripheral part of the tumor. Missense mutations occurring in the cytokeratin 8 (CK-8) gene (RTK 8) at specific codons affects the way the protein products of this gene assume their normal two- and three-dimensional shapes, and may well affect the way the mutant proteins undergo assembly into filamentous structures within the cytoplasm. The defective "protofilament" products apparently accumulate aberrantly, and thus form the distinctive whorled paranuclear inclusions that are characteristic of the rhabdoid cell.
It seems likely that mutations and post-tranlational modifications affecting cytokeratin 8, cytokeratin 18, and vimentin protofilaments are intimately involved in the genesis of the characteristic inclusions and, therefore, of the rhabdoid phenotype. The particulars of this process are poorly understood, but depend in part on the origin of the tumor and stochastic genomic phenomena.
Rhabdoid cells often express protein products suggestive of aggressive, dedifferentiated cells, including neuroendocrine tumor-related products and granulocyte-macrophage colony stimulating factor (GM-CSF). Vimentin, an intermediate filament protein usually associated with non-carcinomatous tumors (i.e. sarcoma), is ubiquitous in rhabdoid cells. Co-expression of cytokeratins and vimentin are associated with cells undergoing epithelial-mesenchymal transition (EMT).
While undifferentiated large-cell lung carcinoma is the most common parent lung tumor from which a rhabdoid phenotype evolves, malignant cells with a rhabdoid phenotype are known to occur in many different histological variants of lung cancer, including adenocarcinoma, sarcomatoid carcinoma, squamous cell carcinoma, combined large cell neuroencrine carcinoma, and mucinous bronchioloalveolar carcinoma  and combined small cell lung carcinoma.
Because LCLC-RP is so rare, no clinical trials have ever been conducted that specifically address treatment of this lung cancer variant. Because LCLC-RP is considered a form of non-small cell lung carcinoma (NSCLC), most physicians adhere to published NSCLC treatment guidelines in rhabdoid carcinoma cases. When possible, radical surgical resection with curative intent is the primary treatment of choice in early stage NSCLC's, and can be administered with or without adjuvant, neoadjuvant, or palliative chemotherapy and/or radiotherapy, depending on the disease stage and performance status of the individual patient.
In numerous clinical trials conducted in NSCLC, several different platinum-based chemotherapy regimens have been shown to be more-or-less equally effective. LCLC's, as a subtype of NSCLC, have traditionally been included in many of these clinical trials, and have been treated like other NSCLC's. More recent trials, however, have shown that some newer agents may have particular effectiveness in prolonging survival of LCLC patients. Pemetrexed, in particular, has shown significant reduction in the hazard ratio for death when used in patients with LCLC. Taxane-based (paclitaxel, docetaxel) chemotherapy was shown to induce a complete and sustained response in a liver metastasis in a case of LCC-RP. A later-appearing metastasis within mediastinal lymph nodes in the same case also showed a durable response to a taxane alone.
There have also been reports of rhabdoid carcinomas expressing vascular endothelial growth factor (VEGF), suggesting that targeted molecular therapy with VEGF blocking monoclonal antibodies such as bevacizumab may be active in these variants. However, evidence suggests that caution must be used when treating a cavitated rhabdoid tumor, one that contains significant components of squamous cell differentiation, or large tumors with containing major blood vessels, due to the potential high risk of life-threatening pulmonary hemorrhage.
A recent study reported a case wherein 2 courses of adjuvant therapy with cisplatin and paclitaxel, followed by oral gefitinib, were used after complete resection. The patient had had no recurrence 34 months later.
As large-volume LCLC-RP may show significant central necrosis and cavitation, prudence dictates that oncologists use extreme caution if contemplating the therapeutic use of bevacizumab, other anti-VEGF compounds, or anti-angiogenesis agents in general, which have been associated with a greatly increased risk of severe hemorrhage and hemoptysis that may be quickly fatal in cavatated pulmonary squamous cell carcinomas. Similar elevated risks have also been noted in tumors located near, or containing, large blood vessels.,
LCLC-RP are considered to be especially aggressive tumors with a dismal prognosis. Many published cases have shown short survival times after diagnosis. Some studies suggest that, as the proportion of rhabdoid cells in the tumor increases, the prognosis tends to worsen, although this is most pronounced when the proportion of rhabdoid cells exceeds 5%. With regard to "parent" neoplasms other than LCLC, adenocarcinomas with rhabdoid features have been reported to have worse prognoses than adenocarcinomas without rhabdoid features, although an "adenocarcinoma with rhabdoid phenotype" tumor variant has not been specifically recognized as a distinct entity under the WHO-2004 classification system.
Interestingly, there are case reports of rhabdoid carcinomas recurring after unusually long periods, which is unusual for a fast-growing, aggressive tumor type. One report described a very early stage patient whose tumor recurred 6 years after initial treatment. Although rapidly progressive, fulminant courses seem to be the rule in this entity, long-term survival has also been noted, even post-metastectomy in late stage, distant metastatic disease.
Although reliable and comprehensive incidence statistics are nonexistent, LCLC-RP is a rare tumor, with only a few hundred cases described in the scientific literature to date. LCLC's made up about 10% of lung cancers in most historical series, equating to approximately 22,000 cases per year in the U.S. Of these LCLC cases, it is estimated that about 1% will eventually develop the rhabdoid phenotype during tumor evolution and progression. In one large series of 902 surgically resected lung cancers, only 3 cases (0.3%) were diagnosed as LCLC-RP. In another highly selected series of large-cell lung carcinoma cases, only 4 of 45 tumors (9%) were diagnosed as the rhabdoid phenotype using the 10% criterion, but another 10 (22%) had at least some rhabdoid cell formation. It appears likely, therefore, that LCLC-RP probably comprises between 0.1% and 1.0% of all lung malignancies.
Similar to nearly all variants of lung carcinoma, large cell lung carcinoma with rhabdoid phenotype appears to be highly related to tobacco smoking. It also appears to be significantly more common in males than in females.
LCLC-RP is generally considered to be an especially aggressive malignancy that metastasizes widely early on in its clinical course. Similar to most other forms of lung carcinoma, LCLC-RP may spread ("metastasize") in three major ways — by local extension and infiltration into surrounding tissues, by lymphatic spread to regional lymph nodes, and through the bloodstream (hematogeneous metastasis) to distant organs and tissues such as the liver, brain, and skeleton.
It has been reported recently that LCLC-RP can metastasize locally within the airways ("aerogeneous spread"), an uncommon mechanism of extension wherein tumor cells migrate along the lung walls and septa, but do not destroy air sacs. Previously, this type of metastatic behavior had not been seen in this particular tumor, being traditionally associated almost exclusively with the "pneumonic" form of pulmonary bronchioloalveolar carcinoma.
As the rhabdoid phenotype may exclusively be associated with certain missense mutations in the CK-8 gene (or, possibly, the vimentin gene — see above), it may prove possible to develop specific monoclonal antibodies against certain peptides in these aberrant gene products that may target only rhabdoid cells with these specific mutations. Recent reports suggest that antibodies may be easier to get into the interior of cells than previously thought.
- Rubenchik I, Dardick I, Auger M (1996). "Cytopathology and ultrastructure of primary rhabdoid tumor of lung". Ultrastruct Pathol. 20 (4): 355–60. PMID 8837343. doi:10.3109/01913129609016337.
- Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; et al., eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN 92-832-2418-3. Retrieved 27 March 2010.
- Beckwith JB, Palmer NF (May 1978). "Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study". Cancer. 41 (5): 1937–48. PMID 206343. doi:10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U.
- Colby TV, Koss MN, Travis WD (1995). "Carcinoid and other neuroendocrine tumors". In Travis WD. Tumors of Lower Respiratory Tract. Washington DC: Armed Forces Institute of Pathology. p. 311.
- Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (December 2001). "The new World Health Organization classification of lung tumours". Eur. Respir. J. 18 (6): 1059–68. PMID 11829087. doi:10.1183/09031936.01.00275301.
- Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R (June 1985). "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases". Hum. Pathol. 16 (6): 569–79. PMID 2987102. doi:10.1016/S0046-8177(85)80106-4.
- Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor". Curr Resp Med Rev. 3: 69–77. doi:10.2174/157339807779941820.
- Vincent MD (August 2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. 16 (4): 9–21. PMC . PMID 19672420. doi:10.3747/co.v16i4.465.
- Travis WD, Travis LB, Devesa SS (January 1995). "Lung cancer". Cancer. 75 (1 Suppl): 191–202. PMID 8000996. doi:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y.
- Saini G, Kumar M, Julka PK, Puri T, Sharma M, Rath GK (2009). "Rhabdoid variant of lung cancer: clinicopathological details of a case and a review of literature". J Cancer Res Ther. 5 (1): 54–7. PMID 19293493. doi:10.4103/0973-1482.48773.
- Shimazaki H, Aida S, Sato M, Deguchi H, Ozeki Y, Tamai S (May 2001). "Lung carcinoma with rhabdoid cells: a clinicopathological study and survival analysis of 14 cases". Histopathology. 38 (5): 425–34. PMID 11422479. doi:10.1046/j.1365-2559.2001.01145.x.
- Cavazza A, Colby TV, Tsokos M, Rush W, Travis WD (February 1996). "Lung tumors with a rhabdoid phenotype". Am. J. Clin. Pathol. 105 (2): 182–8. PMID 8607442.
- Kaneko T, Honda T, Fukushima M, Haniuda M, Komatsu H, Kodama T (October 2002). "Large cell carcinoma of the lung with a rhabdoid phenotype". Pathol. Int. 52 (10): 643–7. PMID 12445136. doi:10.1046/j.1440-1827.2002.01393.x.
- Attems JH, Lintner F (2001). "Pseudomesotheliomatous adenocarcinoma of the lung with rhabdoid features". Pathol. Res. Pract. 197 (12): 841–6. PMID 11795833. doi:10.1078/0344-0338-00170.
- Yilmazbayhan D, Ates LE, Dilege S, Gulluoglu M, Tanju S, Kalayci G (August 2005). "Pulmonary large cell carcinoma with rhabdoid phenotype". Ann Diagn Pathol. 9 (4): 223–6. PMID 16084457. doi:10.1016/j.anndiagpath.2005.04.011.
- Krčedinac Jelena; Panjković Milana; Božanić Snežana; Samardžija Golub; Stojanović Miloš (2011). "Large cell carcinoma with rhabdoid phenotype: case report". Arch Oncol. 19 (1–2): 34–6. doi:10.2298/AOO1102034K.
- Hiroshima K, Shibuya K, Shimamura F, et al. (2003). "Pulmonary large cell carcinoma with rhabdoid phenotype". Ultrastruct Pathol. 27 (1): 55–9. PMID 12554537. doi:10.1080/01913120309949.
- Tamboli P, Toprani TH, Amin MB, et al. (January 2004). "Carcinoma of lung with rhabdoid features". Hum. Pathol. 35 (1): 8–13. PMID 14745719. doi:10.1016/j.humpath.2003.07.019.
- Pardo J, Martinez-Peñuela AM, Sola JJ, et al. (October 2009). "Large cell carcinoma of the lung: an endangered species?". Appl. Immunohistochem. Mol. Morphol. 17 (5): 383–92. PMID 19444077. doi:10.1097/PAI.0b013e31819bfd59.
- Miyagi J, Tsuhako K, Kinjo T, Iwamasa T, Hashimoto H, Ishikawa S (July 2000). "Rhabdoid tumour of the lung is a dedifferentiated phenotype of pulmonary adenocarcinoma". Histopathology. 37 (1): 37–44. PMID 10931217. doi:10.1046/j.1365-2559.2000.00906.x.
- Krauss S, Franke WW (February 1990). "Organization and sequence of the human gene encoding cytokeratin 8". Gene. 86 (2): 241–9. PMID 1691124. doi:10.1016/0378-1119(90)90285-Y.
- Shiratsuchi H, Saito T, Sakamoto A, et al. (February 2002). "Mutation analysis of human cytokeratin 8 gene in malignant rhabdoid tumor: a possible association with intracytoplasmic inclusion body formation". Mod. Pathol. 15 (2): 146–53. PMID 11850543. doi:10.1038/modpathol.3880506.
- Fuller CE, Pfeifer J, Humphrey P, Bruch LA, Dehner LP, Perry A (October 2001). "Chromosome 22q dosage in composite extrarenal rhabdoid tumors: clonal evolution or a phenotypic mimic?". Hum. Pathol. 32 (10): 1102–8. PMID 11679945. doi:10.1053/hupa.2001.28252.
- Itakura E, Tamiya S, Morita K, et al. (September 2001). "Subcellular distribution of cytokeratin and vimentin in malignant rhabdoid tumor: three-dimensional imaging with confocal laser scanning microscopy and double immunofluorescence". Mod. Pathol. 14 (9): 854–61. PMID 11557780. doi:10.1038/modpathol.3880401.
- Wick MR, Ritter JH, Dehner LP (August 1995). "Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion". Semin Diagn Pathol. 12 (3): 233–48. PMID 8545590.
- Hasegawa S, Suda T, Negi K, Hattori Y (January 2007). "Lung large cell carcinoma producing granulocyte-colony-stimulating factor". Ann. Thorac. Surg. 83 (1): 308–10. PMID 17184692. doi:10.1016/j.athoracsur.2006.04.049.
- Vogel AM, Gown AM, Caughlan J, Haas JE, Beckwith JB (February 1984). "Rhabdoid tumors of the kidney contain mesenchymal specific and epithelial specific intermediate filament proteins". Lab. Invest. 50 (2): 232–8. PMID 6198560.
- Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (November 1982). "The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells". Cell. 31 (1): 11–24. PMID 6186379. doi:10.1016/0092-8674(82)90400-7.
- Chetty R (August 2000). "Combined large cell neuroendocrine, small cell and squamous carcinomas of the lung with rhabdoid cells". Pathology. 32 (3): 209–12. PMID 10968398. doi:10.1080/pat.22.214.171.124.
- Song DE, Jang SJ, Black J, Ro JY (September 2007). "Mucinous bronchioloalveolar carcinoma of lung with a rhabdoid component—report of a case and review of the literature". Histopathology. 51 (3): 427–30. PMID 17727492. doi:10.1111/j.1365-2559.2007.02784.x.
- "NCCN Clinical Practice Guidelines in Oncology" (PDF). National Comprehensive Cancer Network. v.2.2010.
- Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G (March 2010). "Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials". Clin Lung Cancer. 11 (2): 126–31. PMID 20199979. doi:10.3816/CLC.2010.n.017.
- Johnson DH, Fehrenbacher L, Novotny WF, et al. (June 2004). "Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer". J. Clin. Oncol. 22 (11): 2184–91. PMID 15169807. doi:10.1200/JCO.2004.11.022.
- Sandler A, Gray R, Perry MC, et al. (December 2006). "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer". N. Engl. J. Med. 355 (24): 2542–50. PMID 17167137. doi:10.1056/NEJMoa061884.
- Reck M, von Pawel J, Zatloukal P, et al. (March 2009). "Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil". J. Clin. Oncol. 27 (8): 1227–34. PMID 19188680. doi:10.1200/JCO.2007.14.5466.
- Chetty R, Bhana B, Batitang S, Govender D (October 1997). "Lung carcinomas composed of rhabdoid cells". Eur J Surg Oncol. 23 (5): 432–4. PMID 9393573. doi:10.1016/S0748-7983(97)93725-2.
- Sheikh SS, Al-Khatti AA, Amr SS (February 2008). "Metachronus malignant rhabdoid tumor of the ileum and adenocarcinoma of lung: a unique case report". Ann Diagn Pathol. 12 (1): 57–61. PMID 18164418. doi:10.1016/j.anndiagpath.2006.06.007.
- Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H (June 2001). "Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology". Cancer. 91 (11): 1992–2000. PMID 11391577. doi:10.1002/1097-0142(20010601)91:11<1992::AID-CNCR1224>3.0.CO;2-5.
- Takei H, Asamura H, Maeshima A, et al. (August 2002). "Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases". J. Thorac. Cardiovasc. Surg. 124 (2): 285–92. PMID 12167788. doi:10.1067/mtc.2002.122523.
- American Cancer Society (2009). "Cancer Facts & Figures 2009" (PDF). Atlanta: American Cancer Society.
- "Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart". World Health Organization Classification of Tumours. (Download Page).
- "Lung cancer page". National Cancer Institute.